Trial Profile
The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 31 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 May 2016 Planned End Date changed to 1 May 2017.
- 28 Mar 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.